Hospital
Mercy Health-St Charles Hospital LLC
Mercy Health-St Charles Hospital LLC was paid $9.63M by Medicaid between Jan 2018 and Feb 2022, across 132 billing codes. Its largest line is 99283, emergency room visit (moderate) — 25% of everything it billed.
33Billing provider infoMERCY HEALTH-ST CHARLES HOSPITAL LLC
OREGON, OH 43616
OREGON, OH 43616
33aNPI1497792568assigned 05/31/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$9.63M
24GClaims278,102
24DCodes billed132
24AFirst – last monthJan 2018 – Feb 2022
Compared with peers
Next to other General Acute Care Hospital providers in Ohio
Rank by total paid#79 of 101
Median peer was paid$22.32M
This provider vs. median0.4×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 76,513 | $2.16M | |
| 2019 | 67,975 | $2.09M | |
| 2020 | 61,375 | $2.53M | |
| 2021 | 64,190 | $2.53M | |
| 2022 | 8,049 | $322K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 25% | 21,711 | 20,874 | $2.44M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 23% | 18,337 | 17,334 | $2.25M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 12% | 8,516 | 7,957 | $1.19M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 5.9% | 6,265 | 6,070 | $570K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 3.9% | 7,708 | 7,211 | $380K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 3.7% | 2,234 | 2,133 | $353K |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 3.1% | 2,968 | 2,859 | $301K |
| 70450 | Computed tomography, head or brain; without contrast material | 2.1% | 883 | 813 | $206K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | 2.1% | 2,241 | 1,424 | $203K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 1.9% | 732 | 688 | $179K |
| 80053 | Comprehensive metabolic panel | 1.7% | 14,245 | 13,230 | $168K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | 1.3% | 371 | 350 | $128K |
120 more codes
| G0378 | Hospital observation service, per hour | 1.2% | 2,263 | $111K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 2,973 | $96K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 2,976 | $67K |
| 62323 | <1% | 134 | $63K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 6,448 | $59K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 3,031 | $58K |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | <1% | 377 | $56K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 861 | $52K |
| 84702 | <1% | 1,814 | $47K | |
| 84484 | <1% | 7,076 | $44K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 35,649 | $42K |
| 87480 | <1% | 2,071 | $38K | |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 149 | $32K |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 1,679 | $32K |
| 87510 | <1% | 2,071 | $32K | |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 854 | $29K |
| 87660 | <1% | 2,094 | $28K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 22,016 | $27K |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 228 | $27K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 158 | $25K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 852 | $21K |
| 80061 | Lipid panel | <1% | 1,344 | $21K |
| 62327 | <1% | 73 | $20K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 1,329 | $18K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 1,207 | $17K |
| 84439 | <1% | 657 | $12K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 3,170 | $11K |
| 71045 | Radiologic examination, chest; single view | <1% | 3,707 | $11K |
| 85027 | <1% | 1,237 | $11K | |
| 81001 | <1% | 8,847 | $10K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 391 | $10K |
| 86780 | <1% | 444 | $9K | |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 39 | $9K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 7,612 | $8K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 345 | $7K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 8,891 | $7K |
| 87070 | <1% | 363 | $7K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 414 | $5K |
| 83880 | <1% | 591 | $5K | |
| 82607 | <1% | 218 | $5K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 4,221 | $5K |
| 87340 | <1% | 277 | $5K | |
| 59025 | Fetal non-stress test | <1% | 63 | $4K |
| 86900 | <1% | 260 | $4K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 1,258 | $4K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 12 | $4K |
| 82746 | <1% | 220 | $4K | |
| 86850 | <1% | 275 | $3K | |
| 83874 | <1% | 242 | $3K | |
| 76801 | <1% | 15 | $2K | |
| 86762 | <1% | 127 | $2K | |
| 86803 | <1% | 56 | $2K | |
| 80076 | <1% | 357 | $2K | |
| 86901 | <1% | 260 | $2K | |
| 84481 | <1% | 167 | $2K | |
| 83690 | <1% | 5,668 | $2K | |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 438 | $2K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 1,384 | $2K |
| 82947 | <1% | 313 | $2K | |
| 83735 | <1% | 1,825 | $1K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 4,237 | $1K |
| 84703 | <1% | 3,674 | $1K | |
| 85379 | <1% | 230 | $1K | |
| 80320 | <1% | 129 | $999.79 | |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 12 | $976.12 |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 44 | $951.82 |
| 87081 | <1% | 59 | $872.71 | |
| 86787 | <1% | 28 | $834.78 | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 12 | $779.20 |
| 76818 | <1% | 17 | $776.91 | |
| 85610 | <1% | 955 | $645.43 | |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 345 | $540.54 |
| 84403 | <1% | 27 | $501.15 | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 3,076 | $478.84 |
| 84436 | <1% | 17 | $386.16 | |
| 81025 | <1% | 1,598 | $379.52 | |
| 83605 | <1% | 89 | $376.86 | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 394 | $368.60 |
| 86317 | <1% | 14 | $297.60 | |
| 86376 | <1% | 12 | $267.22 | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 5,368 | $264.64 |
| 85730 | <1% | 604 | $223.79 | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 505 | $199.71 |
| 81003 | <1% | 574 | $198.15 | |
| 82950 | <1% | 26 | $194.26 | |
| 84480 | <1% | 17 | $193.03 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 3,606 | $191.84 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 3,348 | $140.78 |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 2,439 | $102.68 |
| J2704 | Injection, propofol, 10 mg | <1% | 2,040 | $97.66 |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 717 | $87.46 |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 340 | $75.13 |
| 86140 | <1% | 134 | $56.29 | |
| 80143 | <1% | 43 | $34.99 | |
| 88342 | <1% | 15 | $23.16 | |
| 80179 | <1% | 43 | $17.49 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 405 | $17.42 |
| Q9965 | Low osmolar contrast material, 100-199 mg/ml iodine concentration, per ml | <1% | 798 | $10.00 |
| 83615 | <1% | 116 | $7.15 | |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 62 | $4.19 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 243 | $3.26 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 642 | $0.95 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 24 | $0.66 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 29 | $0.55 |
| 87807 | 0% | 15 | $0.00 | |
| 96376 | 0% | 121 | $0.00 | |
| 99153 | Mod sedat endo service >5yrs | 0% | 12 | $0.00 |
| J0690 | Injection, cefazolin sodium, 500 mg | 0% | 99 | $0.00 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | 0% | 30 | $0.00 |
| J2175 | Injection, meperidine hydrochloride, per 100 mg | 0% | 34 | $0.00 |
| J1170 | Injection, hydromorphone, up to 4 mg | 0% | 52 | $0.00 |
| 00813 | 0% | 25 | $0.00 | |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | 0% | 58 | $0.00 |
| 88304 | 0% | 12 | $0.00 | |
| 74022 | 0% | 13 | $0.00 | |
| 94664 | 0% | 41 | $0.00 | |
| 99152 | 0% | 72 | $0.00 | |
| 00731 | 0% | 25 | $0.00 | |
| 73630 | 0% | 27 | $0.00 | |
| 00811 | 0% | 57 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialALBERS, CRAIG (PRESIDEN & COO ST CHARLES)